Apimeds Pharmaceuticals US (APUS) Profit After Tax (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Profit After Tax for 3 consecutive years, with -$20.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 657.76% year-over-year to -$20.2 million; the trailing twelve-month figure through Jun 2026 stood at -$25.8 million (down 594.89% YoY), and the FY2025 full-year result was -$6.0 million, down 331.74% from the prior year.
• Profit After Tax eased to -$20.2 million in Q2 2026 per APUS's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$296473.0 in Q1 2024 and bottomed at -$20.2 million in Q2 2026.
• Historically, Profit After Tax has averaged -$3.1 million across 3 years, with a median of -$449363.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax slumped 35.73% in 2025, then sank 657.76% in 2026.
• Over 3 years, Profit After Tax stood at -$311633.0 in 2024, then sank by 270.72% to -$1.2 million in 2025, then slumped by 1646.15% to -$20.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$20.2 million, -$1.2 million, and -$1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.